scholarly journals Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials

2021 ◽  
Author(s):  
Monika Graeser ◽  
Simone Schrading ◽  
Oleg Gluz ◽  
Kevin Strobel ◽  
Rachel Würstlein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mr Imaging ◽  
Neoadjuvant Therapy ◽  
Early Breast Cancer ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Early Response ◽  
Breast Cancer Subtypes ◽  
Combined Analysis ◽  
Cancer Subtypes

scholarly journals Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer

2019 ◽  
Vol 176 (1) ◽  
pp. 217-226 ◽  
Author(s):  
Dominique J. P. van Uden ◽  
Marissa C. van Maaren ◽  
Peter Bult ◽  
Luc J. A. Strobbe ◽  
J. J. M. van der Hoeven ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Inflammatory Breast Cancer ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Breast Cancer Subtypes ◽  
Stage Iii ◽  
Cancer Subtypes

scholarly journals Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement

2021 ◽  
pp. 030089162110626
Author(s):  
Elena Guerini-Rocco ◽  
Gerardo Botti ◽  
Maria Pia Foschini ◽  
Caterina Marchiò ◽  
Mauro Giuseppe Mastropasqua ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Early Breast Cancer ◽  
Tumor Response ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Response To Treatment ◽  
Lymph Node Status ◽  
Prognostic Information ◽  
Consensus Statements

Pathologic evaluation of early breast cancer after neoadjuvant therapy is essential to provide prognostic information based on tumor response to treatment (pathologic complete response [pCR] or non-pCR) and to inform therapy decisions after surgery. To harmonize the pathologist’s handling of surgical specimens after neoadjuvant therapy, a panel of experts in breast cancer convened to developed a consensus on six main topics: (1) definition of pCR, (2) required clinical information, (3) gross examination and sampling, (4) microscopic examination, (5) evaluation of lymph node status, and (6) staging of residual breast tumor. The resulting consensus statements reported in this document highlight the role of an accurate evaluation of tumor response and define the minimum requirements to standardize the assessment of breast cancer specimens after neoadjuvant therapy.

Sign in / Sign up

Export Citation Format

Share Document